Lifelong prevention of atherosclerotic cardiovascular disease (ASCVD) through LDL-C control - Means and cost/benefit of sustained very low lifetime LDL-C targets by Mayank Dalakoti, Salim Virani

Connect to this object online.

Heterogeneity in cardio-metabolic risk factors and atherosclerotic cardiovascular disease among Asian groups in the United States by Priyanka Satish, Murrium I. Sadaf, Javier Valero-Elizondo, Gowtham R. Grandhi, Tamer Yahya, Hassan Zawahir, Zulqarnain Javed, Reed Mszar, Bashir Hanif, Ankur Kalra, Salim Virani, Miguel Cainzos-Achirica, Khurram Nasir

Connect to this object online.

US POPULATION QUALIFYING FOR ASPIRIN USE FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: by Athena L. Huang, MD, Ann Marie Navar, MD, PhD, Colby Ayers, MS, Anand Rohatgi, MD, MSCS, Erin Michos, MD, MHS, Salim Virani, MD, PhD, Parag Joshi, MD, MHS, Eric Peterson, MD, MPH, Amit Khera, MD, MSc

Connect to this object online.